In human ACP, the inhibition of IL6 (a SASP factor expressed in mouse and human ACP) results in reduced motility of ACP epithelial tumour cells, suggesting that SASP attenuation may reduce tumour burden in vivo [174]. Here, IL6 is linked to neoplasm.